Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.
Company profile
Ticker
ATXS
Exchange
Website
CEO
Jill C. Milne
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CATABASIS PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Astria Securities Corporation • Quellis Biosciences, LLC ...
ATXS stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
8-K
Departure of Directors or Certain Officers
9 Apr 24
8-K
Other Events
25 Mar 24
8-K
Entry into a Material Definitive Agreement
4 Mar 24
424B5
Prospectus supplement for primary offering
4 Mar 24
10-K
2023 FY
Annual report
4 Mar 24
8-K
Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering
31 Jan 24
424B5
Prospectus supplement for primary offering
31 Jan 24
Transcripts
ATXS
Earnings call transcript
2023 Q3
13 Nov 23
ATXS
Earnings call transcript
2022 Q4
22 Mar 23
ATXS
Earnings call transcript
2021 Q3
10 Nov 21
ATXS
Earnings call transcript
2019 Q4
10 Mar 20
ATXS
Earnings call transcript
2019 Q3
7 Nov 19
ATXS
Earnings call transcript
2019 Q2
8 Aug 19
ATXS
Earnings call transcript
2019 Q1
14 May 19
ATXS
Earnings call transcript
2018 Q4
14 Mar 19
ATXS
Earnings call transcript
2018 Q3
13 Nov 18
ATXS
Earnings call transcript
2018 Q2
9 Aug 18
Latest ownership filings
4
SUNIL AGARWAL
9 Apr 24
3
SUNIL AGARWAL
9 Apr 24
4
Christopher Morabito
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
SC 13G/A
FMR LLC
11 Mar 24
SC 13G/A
BlackRock Inc.
7 Mar 24
SC 13G/A
Fairmount Funds Management LLC
14 Feb 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
Vivo Opportunity, LLC
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 119.97 mm | 119.97 mm | 119.97 mm | 119.97 mm | 119.97 mm | 119.97 mm |
Cash burn (monthly) | 4.72 mm | (no burn) | 6.75 mm | 5.26 mm | 4.75 mm | 4.07 mm |
Cash used (since last report) | 32.07 mm | n/a | 45.85 mm | 35.76 mm | 32.31 mm | 27.68 mm |
Cash remaining | 87.90 mm | n/a | 74.12 mm | 84.21 mm | 87.66 mm | 92.29 mm |
Runway (months of cash) | 18.6 | n/a | 11.0 | 16.0 | 18.4 | 22.7 |
Institutional ownership, Q2 2023
49.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 76 |
Opened positions | 27 |
Closed positions | 17 |
Increased positions | 19 |
Reduced positions | 17 |
13F shares | Current |
---|---|
Total value | 204.26 bn |
Total shares | 26.97 mm |
Total puts | 16.80 k |
Total calls | 22.60 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
FMR | 2.96 mm | $24.68 bn |
Perceptive Advisors | 2.19 mm | $18.24 bn |
Fairmount Funds Management | 1.90 mm | $15.84 bn |
Deep Track Capital | 1.70 mm | $14.14 bn |
Vivo Capital | 1.68 mm | $14.00 bn |
Vivo Opportunity | 1.68 mm | $0.00 |
BLK Blackrock | 1.65 mm | $13.77 bn |
Vanguard | 1.51 mm | $12.55 bn |
Driehaus Capital Management | 1.46 mm | $12.13 bn |
Altium Capital Management | 1.35 mm | $11.22 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 24 | Agarwal Sunil | Stock Option Common Stock | Grant | Acquire A | No | No | 11.4 | 28,200 | 321.48 k | 28,200 |
1 Apr 24 | Christopher Morabito | Common Stock | Sell | Dispose S | No | Yes | 13.5939 | 10,000 | 135.94 k | 0 |
1 Apr 24 | Christopher Morabito | Common Stock | Option exercise | Acquire M | No | Yes | 3.87 | 10,000 | 38.70 k | 10,000 |
1 Apr 24 | Christopher Morabito | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 3.87 | 10,000 | 38.70 k | 80,000 |
8 Feb 24 | Christopher Morabito | Stock Option Common Stock | Grant | Acquire A | No | No | 15.26 | 175,000 | 2.67 mm | 175,000 |
8 Feb 24 | Jill C. Milne | Stock Option Common Stock | Grant | Acquire A | No | No | 15.26 | 534,600 | 8.16 mm | 534,600 |
News
HC Wainwright & Co. Maintains Buy on Astria Therapeutics, Lowers Price Target to $16
23 Apr 24
Wedbush Maintains Outperform on Astria Therapeutics, Raises Price Target to $22
26 Mar 24
HC Wainwright & Co. Maintains Buy on Astria Therapeutics, Maintains $18 Price Target
25 Mar 24
Astria Therapeutics Announces Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
25 Mar 24
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
20 Mar 24
Press releases
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
9 Apr 24
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 Apr 24
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
25 Mar 24
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
4 Mar 24
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 Feb 24